

## **Vortex Biosciences, Inc. Places a VTX-1 System to Investigate Fetal Cell Isolation from Maternal Blood**

October 31, 2019

Vortex Biosciences, a leading provider of circulating tumor cell (CTC) isolation systems and workflows, announces a placement of their VTX-1 Liquid Biopsy System to be used to investigate fetal cell isolation from maternal blood. While extremely rare, circulating fetal cells (CFCs) in maternal blood have a complete fetal genome. Advances in genomic analysis techniques promise to resolve the issues associated with high coverage testing of the low amount of genomic material available in a single cell isolated by the VTX-1.

### About Vortex Biosciences

Vortex Biosciences integrates cancer biology, microfluidic engineering, and informatics to advance cancer research and accelerate the development of innovative diagnostics and therapeutics through tools for isolating intact CTCs. The fully automated Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient's treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. For more information, visit <http://www.vortexbiosciences.com>.